DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Dental Plaque Subcommittee of the Nonprescription Drugs Advisory Committee; **Notice of Meeting**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting is open to the public.

Name of Committee: Dental Plaque Subcommittee of the Nonprescription Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on December 2 and 3, 1998, 8:30 a.m. to 5 p.m.

Location: Advisory Committee Conference Room 1066, 5630 Fishers Lane, Rockville, MD.

Contact Person: Robert L. Sherman or Stephanie A. Mason, Center for Drug Evaluation and Research (HFD-560), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5191, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572) in the Washington, DC area), code 12541. Please call the Information Line for up-to-date information on this meeting.

Agenda: On December 2, 1998, the subcommittee will: (1) Review the ingredients triclosan and the combination of triclosan and zinc citrate; (2) review and vote on the combination of zinc chloride, sodium citrate, hydrogen peroxide, and sodium lauryl sulfate; and (3) discuss comments on the draft subcommittee report. On December 3, 1998, the subcommittee will discuss comments on the draft report and adopt the report.

NMI

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by November 25, 1998. Oral presentations from the public will be scheduled between approximately 8:30 a.m. and 12 m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before November 25, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the Dental Plaque Subcommittee of the Nonprescription Drugs Advisory Committee meeting. Because the agency believes there is some urgency to bring these issues to public discussion and qualified members of the Dental Plaque Subcommittee of the Nonprescription Drugs Advisory Committee were available at this time, the Commissioner concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: November 16, 1998

Michael A. Friedman

Deputy Commissioner for Operations

[FR Doc. 98–???? Filed ??–??–98; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL